Zongertinib Tablets Enter Priority Review for Treating HER2-Mutant NSCLC
According to the CDE website on December 25, Boehringer Ingelheim’s (BI) oral HER2 inhibitor Zongertinib tablets (BI 1810631) have been proposed for inclusion in the priority review process. The drug is intended for treating unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) in adult patients who have undergone prior systemic therapy.
Zongertinib is a selective HER2 inhibitor that covalently binds to the tyrosine kinase domain (TKD) of both wild-type and mutant HER2 receptors, including those with exon 20 mutations. This enhanced selectivity may lead to better tolerability and efficacy. The drug had previously been granted Breakthrough Therapy Designation by the CDE.
In April this year, Boehringer Ingelheim signed a strategic collaboration agreement with China Biopharma. The two companies will leverage their resources to co-develop and commercialize BI's oncology drug pipelines in mainland China, including Zongertinib.
Research indicates that 2%-4% of NSCLC patients in China exhibit HER2 gene mutations. Historically, HER2-mutant NSCLC patients have had poor prognoses, with median overall survival (OS) following a stage IV diagnosis at only 1.6–1.9 years and progression-free survival (PFS) shorter than that of EGFR-mutant and ALK/ROS1-rearranged NSCLC patients.
Beamion LUNG-1, a Phase Ia/Ib first-in-human open-label trial (NCT04886804), included a Phase Ia dose-escalation study evaluating Zongertinib’s efficacy in patients with advanced/metastatic solid tumors harboring any HER2 alteration. The trial identified 120 mg and 240 mg QD as the recommended expansion doses.
As of May 23, 2024, a total of 132 patients in the Ib cohort received Zongertinib at daily doses of 120 mg or 240 mg (n=75/57). Independent Central Review Committee (BICR) evaluations confirmed an objective response rate (ORR) of 66.7%, and tumor reduction of varying magnitudes was observed in 94% of patients across all dose groups.
2026-10-10
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Lotte Chemical Jumps Nearly 13% as Korean Petrochemical Stocks Rally on Supply-Tightening Bets
-
Ammonia Leaks in Iraq and Jordan Put Fertilizer Production and Port Safety on Alert
-
ExxonMobil’s 264,000-bpd Joliet Refinery Shuts After Site-Wide Power Failure
-
Huide Technology Partners with U.S. Firm to Open the Door to Mass Production of Circular TPU
-
LG Chem Teams Up with Jianghua Microelectronics to Advance Semiconductor Ultra-High-Purity IPA
-
From Eggshell to Elixir: EFSA Declares Egg Membrane Collagen Peptides Safe for Adult Supplements
-
Sika in China Under Pressure: The Structural Alarm Behind the 1,500-Job Cut
-
Blue from the Rainforest: EFSA Greenlights Natural “Jagua Blue” as Safe Food Colorant
-
From Ancient Volcanoes to Modern Feed Mills: EFSA Validates Volcanic Zeolite as Safe and Effective Feed Additive
-
Probiotic Promise, Safety Snag: EFSA Gives Mixed Verdict on Multi-Strain Dog Feed Additive
Recommend Reading
-
U.S.-Iran Détente Triggers Oil Price Plunge, Energy and Chemical Sectors Tumble
-
European Petrochemical Weakness Leaves Naphtha Oversupplied as Cracker Demand Struggles
-
Ukraine Strikes Russia’s Perm Refinery Again, Forcing Crude Unit Offline at 260,000-BPD Facility
-
Global Chemical Giants Accelerate Plant Closures and Layoffs as Industry Enters Structural Capacity Rationalization
-
European Diesel Crack Spread Hits Record $74.66 per Barrel as Global Refinery Outages Mount
-
Acetic acid market trends are weak and consolidating
-
Ethyl Acetate Prices Slightly Rise Within a Narrow Range
-
July 27 Polyethylene Terephthalate (PET) Bottle Chip Prices Decline in China
-
Premium Global Chemical Sourcing Requests (17-21 Nov 2025)
-
July Hydrogen Peroxide Market Prices Oscillate and Decline